• Je něco špatně v tomto záznamu ?

Cancer stem cells: Masters of all traits

LYW. Leck, YS. Abd El-Aziz, KJ. McKelvey, KC. Park, S. Sahni, DJR. Lane, J. Skoda, PJ. Jansson

. 2025 ; 1871 (3) : 167549. [pub] 20241023

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009758

Cancer is a heterogeneous disease, which contributes to its rapid progression and therapeutic failure. Besides interpatient tumor heterogeneity, tumors within a single patient can present with a heterogeneous mix of genetically and phenotypically distinct subclones. These unique subclones can significantly impact the traits of cancer. With the plasticity that intratumoral heterogeneity provides, cancers can easily adapt to changes in their microenvironment and therapeutic exposure. Indeed, tumor cells dynamically shift between a more differentiated, rapidly proliferating state with limited tumorigenic potential and a cancer stem cell (CSC)-like state that resembles undifferentiated cellular precursors and is associated with high tumorigenicity. In this context, CSCs are functionally located at the apex of the tumor hierarchy, contributing to the initiation, maintenance, and progression of tumors, as they also represent the subpopulation of tumor cells most resistant to conventional anti-cancer therapies. Although the CSC model is well established, it is constantly evolving and being reshaped by advancing knowledge on the roles of CSCs in different cancer types. Here, we review the current evidence of how CSCs play a pivotal role in providing the many traits of aggressive tumors while simultaneously evading immunosurveillance and anti-cancer therapy in several cancer types. We discuss the key traits and characteristics of CSCs to provide updated insights into CSC biology and highlight its implications for therapeutic development and improved treatment of aggressive cancers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009758
003      
CZ-PrNML
005      
20250429134509.0
007      
ta
008      
250415s2025 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbadis.2024.167549 $2 doi
035    __
$a (PubMed)39454969
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Leck, Lionel Y W $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia; Cancer Drug Resistance & Stem Cell Program, School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
245    10
$a Cancer stem cells: Masters of all traits / $c LYW. Leck, YS. Abd El-Aziz, KJ. McKelvey, KC. Park, S. Sahni, DJR. Lane, J. Skoda, PJ. Jansson
520    9_
$a Cancer is a heterogeneous disease, which contributes to its rapid progression and therapeutic failure. Besides interpatient tumor heterogeneity, tumors within a single patient can present with a heterogeneous mix of genetically and phenotypically distinct subclones. These unique subclones can significantly impact the traits of cancer. With the plasticity that intratumoral heterogeneity provides, cancers can easily adapt to changes in their microenvironment and therapeutic exposure. Indeed, tumor cells dynamically shift between a more differentiated, rapidly proliferating state with limited tumorigenic potential and a cancer stem cell (CSC)-like state that resembles undifferentiated cellular precursors and is associated with high tumorigenicity. In this context, CSCs are functionally located at the apex of the tumor hierarchy, contributing to the initiation, maintenance, and progression of tumors, as they also represent the subpopulation of tumor cells most resistant to conventional anti-cancer therapies. Although the CSC model is well established, it is constantly evolving and being reshaped by advancing knowledge on the roles of CSCs in different cancer types. Here, we review the current evidence of how CSCs play a pivotal role in providing the many traits of aggressive tumors while simultaneously evading immunosurveillance and anti-cancer therapy in several cancer types. We discuss the key traits and characteristics of CSCs to provide updated insights into CSC biology and highlight its implications for therapeutic development and improved treatment of aggressive cancers.
650    _2
$a lidé $7 D006801
650    12
$a nádorové kmenové buňky $x patologie $x metabolismus $7 D014411
650    12
$a nádory $x patologie $x genetika $x metabolismus $x terapie $7 D009369
650    12
$a nádorové mikroprostředí $7 D059016
650    _2
$a zvířata $7 D000818
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Abd El-Aziz, Yomna S $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia; Oral Pathology Department, Faculty of Dentistry, Tanta University, Tanta, Egypt
700    1_
$a McKelvey, Kelly J $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia
700    1_
$a Park, Kyung Chan $u Proteina Co., Ltd./Seoul National University, Seoul, South Korea
700    1_
$a Sahni, Sumit $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia
700    1_
$a Lane, Darius J R $u Melbourne Dementia Research Centre, The Florey Institute of Neuroscience & Mental Health, The University of Melbourne, Parkville, VIC, Australia
700    1_
$a Skoda, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. Electronic address: jan.skoda@sci.muni.cz
700    1_
$a Jansson, Patric J $u Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, St Leonards, NSW, Australia; Cancer Drug Resistance & Stem Cell Program, School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. Electronic address: patric.jansson@sydney.edu.au
773    0_
$w MED00000539 $t Biochimica et biophysica acta. Molecular basis of disease $x 1879-260X $g Roč. 1871, č. 3 (2025), s. 167549
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39454969 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134505 $b ABA008
999    __
$a ok $b bmc $g 2311247 $s 1246839
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 1871 $c 3 $d 167549 $e 20241023 $i 1879-260X $m Biochimica et biophysica acta. Molecular basis of disease $n Biochim Biophys Acta Mol Basis Dis $x MED00000539
LZP    __
$a Pubmed-20250415
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace